文献速递心律失常

Brugada综合征致病基因报道的重新评估:基于证据的基因有效性评价

Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome.
PubMed 文献 · Circulation · 2018-01-01

该研究由3个基因 curation 团队采用半定量评分系统,对诊断实验室常规检测的21个Brugada综合征(BrS)基因进行临床有效性评估。结果显示仅SCN5A被分类为决定性证据,其余20个基因均为有限证据;经临床专家小组复审后,这20个基因被重新归类为疾病因果性存在争议。结论质疑了除SCN5A外所有临床检测基因与BrS的关联有效性。

要点

  • 仅SCN5A有决定性证据支持与Brugada综合征的因果关联。
  • 其余20个常规检测基因证据有限,复审后归为因果性争议。
  • 建议在临床使用前对报道的基因-疾病关联进行系统循证评估。

核心结论

  • 除SCN5A外,所有临床检测并报道与BrS相关的基因,其临床有效性均受到质疑。

研究设计与样本

  • 研究组装了3个基因 curation 团队,采用基于证据的半定量评分系统独立评估基因-疾病关联。
  • 评估对象为诊断实验室检测的21个Brugada综合征基因,分类由临床领域专家小组复审并可修改。

主要发现

  • 在21个 curated 基因中,生物信息学 curation 团队仅将SCN5A分类为决定性证据,其余所有基因均为有限证据。
  • 经临床领域专家小组全面复审后,20个有限证据基因均被重新分类为对BrS疾病因果性主张存在争议。

关键数值与推荐

  • 基因分类采用有限、中等、强、决定性四级证据等级。
  • 21个基因中1个(SCN5A)为决定性证据,20个为有限证据,复审后20个改为争议。

临床怎么用

  • 临床基因检测报告解读时应审慎对待除SCN5A外其他基因与BrS的关联声称。
  • 在患者护理中使用基因-疾病关联前,应进行系统的循证评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Implicit in the genetic evaluation of patients with suspected genetic diseases is the assumption that the genes evaluated are causative for the disease based on robust scientific and statistical evidence. However, in the past 20 years, considerable variability has existed in the study design and quality of evidence supporting reported gene-disease associations, raising concerns of the validity of many published disease-causing genes. Brugada syndrome (BrS) is an arrhythmia syndrome with a risk of sudden death. More than 20 genes have been reported to cause BrS and are assessed routinely on genetic testing panels in the absence of a systematic, evidence-based evaluation of the evidence supporting the causality of these genes. METHODS: We evaluated the clinical validity of genes tested by diagnostic laboratories for BrS by assembling 3 gene curation teams. Using an evidence-based semiquantitative scoring system of genetic and experimental evidence for gene-disease associations, curation teams independently classified genes as demonstrating limited, moderate, strong, or definitive evidence for disease causation in BrS. The classification of curator teams was reviewed by a clinical domain expert panel that could modify the classifications based on their independent review and consensus. RESULTS: Of 21 genes curated for clinical validity, biocurators classified only 1 gene ( SCN5A) as definitive evidence, whereas all other genes were classified as limited evidence. After comprehensive review by the clinical domain Expert panel, all 20 genes classified as limited evidence were reclassified as disputed with regard to any assertions of disease causality for BrS. CONCLUSIONS: Our results contest the clinical validity of all but 1 gene clinically tested and reported to be associated with BrS. These findings warrant a systematic, evidence-based evaluation for reported gene-disease associations before use in patient care.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Hosseini SM, Kim R, Udupa S, et al. Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome. Circulation. 2018. PMID: 29959160. doi:10.1161/CIRCULATIONAHA.118.035070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。